India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of disruptions ...

Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology ...

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and ...

The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-based therapies, such as probiotics, prebiotics, and ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health.

Monroe Biomedical Research (MBR), a dedicated clinical trial site, is growing its footprint to enhance early-phase clinical trials and attract more research opportunities to North Carolina.

Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...